Lawrence B Afrin1, Sally Self2, Jeremiah Menk3, John Lazarchick2. 1. Division of Hematology, Oncology and Transplantation, University of Minnesota (UMN), Minneapolis, Minnesota. Electronic address: afrinl@umn.edu. 2. Department of Pathology and Laboratory Medicine, Medical University of South Carolina, Charleston, South Carolina. 3. Clinical and Translational Science Institute (CTSI), University of Minnesota, Minneapolis, Minnesota.
Abstract
BACKGROUND: Mast cell activation syndrome (MCAS), a recently recognized nonneoplastic mast cell disease driving chronic multisystem inflammation and allergy, appears prevalent and thus important. We report the first systematic characterization of a large MCAS population. METHOD: Demographics, comorbidities, symptoms, family histories, physical examination and laboratory findings were reviewed in 298 retrospective and 115 prospective patients with MCAS. Blood samples from prospective subjects were examined by flow cytometry for clonal mast cell disease and tested for cytokines potentially driving the monocytosis frequent in MCAS. RESULTS: Demographically, white females dominated. Median ages at symptom onset and diagnosis were 9 and 49 years, respectively (range: 0-88 and 16-92, respectively) and median time from symptom onset to diagnosis was 30 years (range: 1-85). Median numbers of comorbidities, symptoms, and family medical issues were 11, 20, and 4, respectively (range: 1-66, 2-84, and 0-33, respectively). Gastroesophageal reflux, fatigue and dermatographism were the most common comorbidity, symptom and examination finding. Abnormalities in routine laboratories were common and diverse but typically modest. The most useful diagnostic markers were heparin, prostaglandin D2, histamine and chromogranin A. Flow cytometric and cytokine assessments were unhelpful. CONCLUSIONS: Our study highlights MCAS׳s morbidity burden and challenging heterogeneity. Recognition is important given good survival and treatment prospects.
BACKGROUND:Mast cell activation syndrome (MCAS), a recently recognized nonneoplastic mast cell disease driving chronic multisystem inflammation and allergy, appears prevalent and thus important. We report the first systematic characterization of a large MCAS population. METHOD: Demographics, comorbidities, symptoms, family histories, physical examination and laboratory findings were reviewed in 298 retrospective and 115 prospective patients with MCAS. Blood samples from prospective subjects were examined by flow cytometry for clonal mast cell disease and tested for cytokines potentially driving the monocytosis frequent in MCAS. RESULTS: Demographically, white females dominated. Median ages at symptom onset and diagnosis were 9 and 49 years, respectively (range: 0-88 and 16-92, respectively) and median time from symptom onset to diagnosis was 30 years (range: 1-85). Median numbers of comorbidities, symptoms, and family medical issues were 11, 20, and 4, respectively (range: 1-66, 2-84, and 0-33, respectively). Gastroesophageal reflux, fatigue and dermatographism were the most common comorbidity, symptom and examination finding. Abnormalities in routine laboratories were common and diverse but typically modest. The most useful diagnostic markers were heparin, prostaglandin D2, histamine and chromogranin A. Flow cytometric and cytokine assessments were unhelpful. CONCLUSIONS: Our study highlights MCAS׳s morbidity burden and challenging heterogeneity. Recognition is important given good survival and treatment prospects.
Authors: Peter Valent; Cem Akin; Michel Arock; Knut Brockow; Joseph H Butterfield; Melody C Carter; Mariana Castells; Luis Escribano; Karin Hartmann; Philip Lieberman; Boguslaw Nedoszytko; Alberto Orfao; Lawrence B Schwartz; Karl Sotlar; Wolfgang R Sperr; Massimo Triggiani; Rudolf Valenta; Hans-Peter Horny; Dean D Metcalfe Journal: Int Arch Allergy Immunol Date: 2011-10-27 Impact factor: 2.749
Authors: Erica Cohen; Roger Bolus; Dinesh Khanna; Ron D Hays; Lin Chang; Gil Y Melmed; Puja Khanna; Brennan Spiegel Journal: Dig Dis Sci Date: 2014-05-09 Impact factor: 3.199
Authors: Luis Escribano; Iván Alvarez-Twose; Laura Sánchez-Muñoz; Andres Garcia-Montero; Rosa Núñez; Julia Almeida; Maria Jara-Acevedo; Cristina Teodósio; Mónica García-Cosío; Carmen Bellas; Alberto Orfao Journal: J Allergy Clin Immunol Date: 2009-07-09 Impact factor: 10.793
Authors: Leonard B Weinstock; Arthur S Walters; Jill B Brook; Zahid Kaleem; Lawrence B Afrin; Gerhard J Molderings Journal: J Clin Sleep Med Date: 2020-01-14 Impact factor: 4.062
Authors: Michael Kurin; Abbinaya Elangovan; Muhammed Mustafa Alikhan; Basmah Al Dulaijan; Eli Silver; David C Kaelber; Gregory Cooper Journal: Neurogastroenterol Motil Date: 2021-09-17 Impact factor: 3.960
Authors: Kenneth A Mayuga; Artur Fedorowski; Fabrizio Ricci; Rakesh Gopinathannair; Jonathan Walter Dukes; Christopher Gibbons; Peter Hanna; Dan Sorajja; Mina Chung; David Benditt; Robert Sheldon; Mirna B Ayache; Hiba AbouAssi; Kalyanam Shivkumar; Blair P Grubb; Mohamed H Hamdan; Stavros Stavrakis; Tamanna Singh; Jeffrey J Goldberger; James A S Muldowney; Mark Belham; David C Kem; Cem Akin; Barbara K Bruce; Nicole E Zahka; Qi Fu; Erik H Van Iterson; Satish R Raj; Fetnat Fouad-Tarazi; David S Goldstein; Julian Stewart; Brian Olshansky Journal: Circ Arrhythm Electrophysiol Date: 2022-09-08
Authors: Leonard B Weinstock; Jill B Brook; Arthur S Walters; Ashleigh Goris; Lawrence B Afrin; Gerhard J Molderings Journal: J Clin Sleep Med Date: 2022-05-01 Impact factor: 4.324
Authors: G J Molderings; F L Dumoulin; J Homann; B Sido; J Textor; M Mücke; G J Qagish; R Barion; M Raithel; D Klingmüller; V S Schäfer; H J Hertfelder; D Berdel; G Tridente; L B Weinstock; L B Afrin Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 2020-05-06 Impact factor: 3.000